Mohamed Shala, MD
Interventional Cardiology · Memphis, TNNPI 1841277308
Payments from drug & device makers
Across 315 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$892
- Novartis$810
- Medtronic$662
- Philips North America LLC$564
- Actelion Pharmaceuticals US, Inc.$474
- Johnson & Johnson$295
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,33099%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 50 | $892 |
| Novartis | 54 | $810 |
| Medtronic | 37 | $662 |
| Philips North America LLC | 35 | $564 |
| Actelion Pharmaceuticals US, Inc. | 32 | $474 |
| Johnson & Johnson | 23 | $295 |
| E.r. Squibb & Sons, L.L.C. | 14 | $255 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $157 |
| Shockwave Medical, Inc | 2 | $151 |
| Amarin Pharma, Inc. | 8 | $144 |
| Amgen | 9 | $128 |
| Sanofi-aventis U.S. LLC | 5 | $103 |
| Boston Scientific | 3 | $72 |
| Tactile Systems Technology Inc | 1 | $55 |
| Abbott | 2 | $50 |
| Merck | 3 | $49 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Astellas Pharma US Inc | 2 | $42 |
| Akcea Therapeutics, Inc. | 2 | $41 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| GE HealthCare | 2 | $37 |
| Cordis US CORP. | 1 | $34 |
| Baxter Healthcare | 2 | $32 |
| Abiomed | 1 | $30 |
| Cvrx, Inc. | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Silk Road Medical, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Atricure, Inc. | 1 | $14 |
| Altathera Pharmaceuticals LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,360 in reported general payments places this provider in the 30th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,070 | $915,527 |
| XareltoRivaroxaban | 241 | $235,629 |
| EntrestoSacubitril/Valsartan | 111 | $135,337 |
| JardianceEmpagliflozin | 151 | $133,986 |
| Repatha SureclickEvolocumab | 114 | $73,686 |
| BrilintaTicagrelor | 26 | $21,292 |
| OzempicSemaglutide | 20 | $18,235 |
| MounjaroTirzepatide | 11 | $15,141 |
| FarxigaDapagliflozin Propanediol | 18 | $14,230 |
| Metoprolol Succinate | 1,298 | $14,228 |
| Rosuvastatin Calcium | 1,054 | $13,821 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 349 | $13,543 |
| Praluent PenAlirocumab | 20 | $13,415 |
| EdarbiAzilsartan Medoxomil | 26 | $10,920 |
| VascepaIcosapent Ethyl | 24 | $10,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $892 | $915,5271,070 claims |
| Johnson & JohnsonXarelto | $295 | $235,629241 claims |
| NovartisEntresto | $810 | $135,337111 claims |
| Boehringer IngelheimJardiance | $15 | $133,986151 claims |
| Novo NordiskOzempic | $19 | $18,23520 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $22 | $10,92026 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $42 | $2,21412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Memphis
- Joseph WeinsteinMemphis$653K
- Claro DiazMemphis$184K
- Dwight DishmonMemphis$139K
- Benjamin WallerMemphis$53K
- Stevan HimmelsteinMemphis$25K
- Michael MorseNashville$3.5M
- Charles TreasurePowell$3M
- Colin BarkerNashville$2.1M
- Brian JeffersonNashville$2.1M
- Malcolm FosterKnoxville$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.